Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers identified two novel peptidylarginine deiminases from treated rat keratinocytes, both showing enzyme activity with PAD‐R11 reflecting a characteristic of epidermal enzymes.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This study identified 71 SNPs linked to black wool traits in Qira sheep and found that specific mutations in the TYRP1 gene significantly correlate with coat color variations, providing insights for their genetic selection and conservation.

This article explores the interactions between retinoids and the immune system but reports no new clinical results related to their role in hair cycle control.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This report identifies a novel mutation in the ST14 gene in a female with autosomal recessive ichthyosis with hypotrichosis, highlighting similar features to previously reported cases.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

This study reported that using the Sinclair Shedding Scale and intralesional corticosteroid injections may help diagnose and manage alopecia areata incognita in women experiencing excessive hair shedding without clear diagnostic indicators.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

In this study, the researchers found no superiority of combining 308-nm excimer laser with intralesional corticosteroid over corticosteroid alone for treating frontal fibrosing alopecia, and reported side effects such as erythema and postinflammatory hyperpigmentation in both treatment groups.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This review compiles existing research on infrared radiation's effects on human skin, noting both its potential harmful thermal impacts and encouraging therapeutic applications, but reports no new clinical results.

The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study reports significant hair regrowth in two alopecia areata patients resistant to intralesional corticosteroids after treatment with intralesional polydeoxyribonucleotide.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This narrative review discusses the role and importance of rheumatologists in managing autoimmune interstitial lung disease and emphasizes the need for enhanced collaboration with respiratory physicians to improve diagnosis, management, and outcomes; no new clinical results are reported.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this study, freezing gamma-irradiated amniotic fluid increased hair follicles and accelerated the transition to the anagen stage in rats, suggesting potential for treating hair loss safely and effectively.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that quaternary ammonium iminofullerenes (IFQA) can alleviate oxidative stress in maize caused by hydrogen peroxide, promoting root growth by enhancing antioxidant cycles and reducing ROS accumulation.